Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of rIX-FP in Hemophilia B
NCT01361126Phase 2Completed
- Sponsor
- CSL Limited
- Start
- Jul 2011
- Primary completion
- Jun 2012
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of albutrepenonacog alfa in hemophilia B (HB), sponsored by CSL Limited. Started Jul 2011; status: completed.
02
Drugs
albutrepenonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT01361126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01361126.